Actualités

It's not the news that AbbVie needed, given the challenging year it is having.

AbbVie (NYSE:ABBV) presented new long term clinical and real world data for its gastroenterology portfolio at the 2026 Digestive Disease Week. The data highlighted SKYRIZI and RINVOQ in Crohn's disease and ulcerative colitis, with reports of sustained patient benefits and strong real world performance. These findings relate to AbbVie's efforts to address unmet clinical needs and reinforce its position in inflammatory bowel disease treatments. AbbVie is a large biopharmaceutical company with...

AbbVie has lagged the broader market over the past year, although Wall Street analysts remain moderately optimistic about the company’s long-term growth prospects and pipeline strength.

This mortgage REIT generates income by originating and managing commercial real estate loans across the United States.

Blackstone Mortgage Trust originates senior commercial real estate loans globally, generating income primarily from interest and dividends.

AbbVie (NYSE:ABBV) told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-expected revenue and continued investment in its drug pipeline and business development. Rob Michael, AbbVie’s chairman and chief executive officer,

This article explains in straightforward terms whether AbbVie at around US$202 per share still offers value or whether most of the opportunity has already been priced in. The stock has recently been mixed, with a 4.1% decline over the last 7 days and a 1.8% decline over the last 30 days. It still shows returns of 12.8% over 1 year, 54.0% over 3 years, and 109.7% over 5 years. Recent coverage has focused on AbbVie's position as a large US pharmaceuticals and biotech company and on how...

IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.

AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for the next 15 years. On April 30, AbbVie, in partnership with adMare BioInnovations, named RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award. This national competition is designed to support Quebec’s life sciences sector by supporting early-stage companies that align with […]

Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD) and Vanguard High Dividend Yield ETF (NYSEARCA: VYM) sit on most income investors’ shortlists. Both entered 2026 with fresh distributions and updated holdings. The two funds chase dividends through very different rule sets, and the gap between them is wider than the surface suggests. Quality Screen vs. Yield ... Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain

Q1 earnings show this Dividend King still looks built for the long term.

In recent weeks, AbbVie reported first-quarter 2026 revenue of US$15,002 million, while also securing new Canadian formulary listings and reimbursement progress for SKYRIZI in ulcerative colitis alongside fresh clinical and regulatory updates for SKYRIZI and RINVOQ across inflammatory and autoimmune diseases. Together with an ongoing dividend record and advances in areas such as immunology, gastroenterology and oncology partnerships, these developments highlight how AbbVie is leaning on its...

They have combined for 118 years of consecutive dividend increases.

Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can be redeployed or spent without selling property or waiting on private placements. Pharma is one of the few sectors where mature franchises, regulatory ... 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash

Clinical Trials Arena rounds up the key readouts from the 2026 Digestive Disease Week conference held in Chicago.

These stocks check off multiple boxes for income investors.

Over the last 7 days, the United States market has remained flat, yet it has seen a significant rise of 28% over the past year, with earnings projected to grow by 16% annually in the coming years. In such an environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervaluation.

By holding these top income stocks in your portfolio, you can have a position in some great companies while also generating cash flow each month.

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The United States market has remained flat over the last week but is up 28% over the past year, with earnings expected to grow by 16% per annum. In such a climate, identifying undervalued stocks that offer significant discounts can present valuable opportunities for investors seeking growth potential.